For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?
Ames
David
D
Department of Psychiatry, University of Melbourne, Australia. ipaj-ed@unimelb.edu.au
Kaduszkiewicz
Hanna
H
van den Bussche
Hendrik
H
Zimmermann
Thomas
T
Birks
Jacqueline
J
Ashby
Deborah
D
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000453:epidemiology*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D000077265:Donepezil; D005702:Galantamine / Q000627:therapeutic use*; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D010880:Piperidines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil